AI-Powered training cuts hamstring injury risk in pro footballers
NCT ID NCT07650006
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used artificial intelligence to analyze sprinting motions and identify football players at risk for hamstring injuries. Players at medium or high risk then followed a four-month exercise program called FUNBALL, which has been shown to reduce thigh muscle injuries by about 38%. The researchers also measured how the program affected speed, agility, balance, and thinking skills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FUNBALL Prevention Program (structured exercise intervention)
- What this could lead to
- If successful, this could provide a simple, evidence-based exercise program to reduce hamstring injuries in football players.
- What could go wrong
- This is a small, completed study with only 30 participants, so results may not apply to all players. The AI-based risk assessment is still experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbulspor Ömer Sarıalioglu Football Team Facilitu
Istanbul, Büyükçekmece, 34537, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test